Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 587 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aspirin Clear all
Completed Phase 2 Interventional Results available

Trial of Aspirin and Arginine Restriction in Colorectal Cancer

NCT00578721
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Aspirin
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

NCT01426438
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Niacin, Aspirin, Fenofibrate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Not applicable Interventional Results available

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease

NCT00323258
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
oral education & written tips for remembering medications, pill box, pocket medication card, sharing information with community pharmacist, Medication use evaluations by community pharmacist, informing physician if patient has stopped a medication, Routine discharge counseling, Letter to physician/discharge summary
Behavioral · Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 4, 2026, 6:29 PM EDT
Recruiting Phase 2 Interventional

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

NCT06866964
View directory record Official record
Conditions
Germ Cell Tumor, Testicular Cancer
Interventions
Low-dose ASA
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 4, 2026, 6:29 PM EDT
Terminated Phase 4 Interventional Results available

The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia

NCT03735433
View directory record Official record
Conditions
Preeclampsia
Interventions
162mg aspirin dose
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Phase 2 Interventional

Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)

NCT00054938
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus
Interventions
pravastatin, aspirin, ramipril, Vitamins: B6, B12, and folate, heart health educational program
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Collaborative Lifestyle Intervention Program in Knee Osteoarthritis Patients

NCT02835326
View directory record Official record
Conditions
Osteoarthritis
Interventions
Exercise and Dietary Weight Loss, Walk with Ease
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Early Phase 1 Interventional

The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy

NCT00727948
View directory record Official record
Conditions
Breast Cancer, Angiogenesis
Interventions
Aspirin
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Not applicable Interventional

The Effects of MAP and EtCO2 on Venous Sinus Pressures

NCT03867461
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Venous Sinus Stenting, Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range), Adjustment to Mean Arterial Pressure (100-110 mmHg range), Adjustment to Mean Arterial Pressure (60-80 mmHg range), Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 4, 2026, 6:29 PM EDT
Completed No phase listed Observational

Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients

NCT01364779
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Sep 4, 2026, 6:29 PM EDT
Withdrawn Not applicable Interventional

Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation

NCT03232450
View directory record Official record
Conditions
Foramen Ovale, Patent
Interventions
Aspirin, Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 4, 2026, 6:29 PM EDT
Not yet recruiting Phase 4 Interventional

A Clinical Trial of Antiplatelets in Psoriasis

NCT07744191
View directory record Official record
Conditions
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Interventions
Aspirin, Clopidogrel, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

NCT01994720
View directory record Official record
Conditions
Acute Ischaemic Stroke, Transient Ischaemic Attack
Interventions
ticagrelor, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
13,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
115
States / cities
Montgomery, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 112 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 4, 2026, 6:29 PM EDT
Recruiting Phase 2 Interventional

A Polypill for Acute Coronary Syndrome

NCT07032389
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Polypill
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event

NCT01578629
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack (TIA)
Interventions
Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin, Placebo vehicle control
Other
Lead sponsor
Andrew Slivka
Other
Eligibility
40 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 4, 2026, 6:29 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762703
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 6:29 PM EDT
Terminated Phase 3 Interventional Results available

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

NCT02556203
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic Acid (ASA), Clopidogrel, Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
31
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 4, 2026, 6:29 PM EDT
Withdrawn Phase 3 Interventional

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

NCT05104229
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Venous Thromboembolism
Interventions
Aspirin 81Mg Ec Tab, Standard of Care
Drug
Lead sponsor
Stefan Holubar MD MS FACS, FASCRS
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 4, 2026, 6:29 PM EDT
Terminated Not applicable Interventional Results available

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

NCT01781611
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
extended release dipyridamole 200mg/aspirin 25mg, 81mg aspirin
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 4, 2026, 6:29 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

162 mg of Aspirin for Prevention of Preeclampsia

NCT05221164
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin 162 mg
Drug
Lead sponsor
Methodist Medical Center of Illinois
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 4, 2026, 6:29 PM EDT
Completed Phase 4 Interventional Results available

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 95 Years
Enrollment
4,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 4, 2026, 6:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Low Dose Aspirin Studied With the AggreGuide

NCT01603966
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Not listed
Lead sponsor
Edward R. Teitel, M.D.
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Sep 4, 2026, 6:29 PM EDT